Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

July 19, 2021

Study Completion Date

July 19, 2021

Conditions
Acute Decompensated Heart Failure
Interventions
DRUG

BMS-986259

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (18)

1180

Local Institution - 0009, Ciudad de Buenos Aires

5000

Local Institution - 0007, Alberdi

Local Institution - 0028, Córdoba

5006

Local Institution - 0025, Córdoba

11527

Local Institution - 0011, Athens

12808

Local Institution - 0020, Prague

912001

Local Institution, Jerusalem

4941492

Local Institution, Petah Tikva

6423906

Local Institution - 0014, Tel Aviv

X5000EPU

Local Institution - 0010, Córdoba

C1093AAS

Local Institution, Buenos Aires

274 01

Nemocnice Slany-Interna - kardiologicka ambulance, Slaný

142 33

Local Institution - 0022, Athens

15 276

Local Institution - 0034, Bialystok

50-556

Local Institution - 0030, Wrocaw

54-049

Local Institution - 0027, Wroclaw

EH16 4SA

Local Institution, Edinburgh

SN3 6BB

Local Institution, Swindon

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure | Biotech Hunter | Biotech Hunter